Key result
Enhanced Recovery After Surgery (ERAS) protocols for neurosurgical brain tumors require a simplified, procedure-specific approach distinguishing short-term from long-term functional recovery.
Answers are grounded in this paper and cite their sources.
This letter advocates for simplified, procedure-specific ERAS guidelines for neurosurgical tumor patients, emphasizing the need for solid evidence and differentiation between short- and long-term recovery outcomes.
To the Editor: The concept of “fast-track” surgery was initiated in 1997,1 and the “Enhanced recovery after surgery” (ERAS) Society was formed in 2001 with the establishment of the ERAS Study group and the development of the first ERAS protocol.2 Since then, clinicians worldwide have embraced the idea. Mounting evidence has confirmed that an approach aiming to mobilize the patient and discharge them without unnecessary delays is associated with improved outcomes regardless of surgical specialty. The simple question at the core of the concept is, “Why (is the patient still) in the hospital?” Answering this question, and secondary questions derived from it, has led to strategies that benefit not only patients through increased quality in their care, but frequently also hospital cost reduction. In some surgical fields, including neurosurgery, implementation of ERAS protocols has been delayed mainly because of their multidisciplinary structure.3 Neurosurgery features some of the most technically advanced surgical procedures, but several central ERAS-related questions remain unanswered in this specific patient population. Of the many suggested components in some ERAS programs, several have little or no effect on patient outcomes,4,5 and attention must be directed toward those that have been shown by solid evidence to enhance recovery after specific surgery to simplify and facilitate implementation.3 The latest ERAS guideline on tumor craniotomies from 2016 by Hagan et al6 mentions 17 factors to be addressed, but many without procedure-specific evidence. Thus, ERAS items should not be confused with general information pathways and high standard of basic care, and items like “preoperative counselling” are general across all surgical fields. Also, too many ERAS components can impede the implementation of each other. It is important that the authors of ERAS guidelines identify the procedure-specific ERAS components that have shown the most benefit and then focus on these components. For example, after a tumor craniotomy comprehensive rehabilitation has been shown to benefit the patients,7 mobilization in itself may not suffice for this particular group as a single standing ERAS item. “Strong for” recommendations based on a low to moderate evidence rating can be problematic, especially if the guideline does not distinguish between short-term (eg, length of stay and pain) and long-term outcomes (eg, chronic pain issues and complication rates), as a shorter length of stay may be unimportant for the patient and the clinicians if the postdischarge recovery does not improve after the intervention. ERAS was initially developed based on fast-track colorectal patients. However, several of the core interventions have proven effective across surgical fields, for example an opioid-sparing based but effective pain control.8,9 Tumor craniotomies are painful procedures,10 and optimal pain management can be achieved with an opioid-sparing approach including paracetamol and nonsteroidal anti-inflammatory drugs/COX-2 inhibitors.11,12 Even so, opioids are still an important rescue part of the pain management protocol for tumor craniotomies. The routine use of alternatives like gabapentinoids, which have limited clinical benefit, and introducing a risk of harms should be avoided.11,13 Other interventions, eg, scalp shaving as well as minimally invasive craniotomies and endoscopic approaches, have been widely adopted based on limited evidence but may have negligible effects in neurosurgical tumor patients.6 One study of an ERAS program for elective craniotomy, which consisted of pre-, intra-, and postoperative interventions, reported a shorter length of stay, less pain, reduced time with an indwelling urinary catheter, and shorter time to oral intake. However, it is unclear which of the many interventions were the true drivers of the better outcomes.14 Data on compliance are also needed, as both implementation and perseverance over time are returning issues across surgical fields and ERAS programs.15 We suggest a simplified approach for the development of a neurosurgical tumor ERAS program until more data are available on the clinical benefit of the different interventions.16,17 This will make implementation realistic across departmental barriers. Over time, such interventions may be differentiated by patient-specific levels of risk (frailty, specific comorbidities, preoperative chronic pain, etc). One example of such differentiation in tumor craniotomy patients is postoperative seizure activity.18 Seizures are common both pre- and postoperatively; of glioblastoma patients, 23% suffer from seizures at 12 mo postoperatively, and absence of seizures correlates to a better Karnofsky performance score.19 Pre-emptive treatment of postoperative seizures thus has the potential to enhance the postoperative recovery but warrants further research to identify patients at risk and optimal treatment strategies. Also, future research should divide measures of recovery into short- and long-term outcomes and complications. In summary, simple and evidence-based guidelines for enhanced recovery are likely to ensure successful implementation of a program with clear benefit for the patients. Perioperative neurosurgical recommendations will profit from a separation of the interventions needed to enhance an early (eg, in-hospital) recovery from those targeting postdischarge functional recovery. Also, it is important to distinguish between evidence acquired from other surgical fields vs evidence related to the specific procedures done (and problems encountered) in neurosurgery. Thus, future research can be focused on unanswered questions related to perioperative neurosurgery-specific issues in the specific patient groups at risk. Funding This study did not receive any funding or financial support. Disclosures The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.
No takes yet. Share an insight, caveat, or question.
Sørensen et al. (2021) conducted a letter in Brain tumors. Enhanced Recovery After Surgery (ERAS) protocols was evaluated. Enhanced Recovery After Surgery (ERAS) protocols for neurosurgical brain tumors require a simplified, procedure-specific approach distinguishing short-term from long-term functional recovery.
Synapse has enriched 10 related papers. Consider them for comparative context: